Sanguine Selects Dr. Robert Kwun To Join Its Medical Advisory Board
Wednesday December 8, 6:30 AM EST
PASADENA, Calif., Dec 8, 2004 (BUSINESS WIRE) -- Sanguine Corporation (SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells, announced that it has selected a new Medical Advisory Board Member. Dr. Robert Kwun, a retina surgeon, has been retained to evaluate the use of PHER-O2 in ophthalmic surgery.
Dr Kwun received his undergraduate degree from Harvard University and his Doctor of Medicine degree from Columbia University in New York, New York. Dr. Kwun's clinical training includes Columbia University's Manhattan Eye, Ear and Throat Hospital, Los Angeles Children's - USC Medical Center, the Doheny Eye Institute, and New York's St. Vincent's Hospital. Dr. Kwun has received numerous honors and awards in retinal surgery in addition to having authored or co-authored many articles in the area of macular degeneration and other areas ophthalmic surgery.
Thomas Drees, Ph.D., chairman and CEO of Sanguine Corporation, stated, "We are extremely excited to add Dr. Kwun to our Medical Advisory Board. We look forward to his immediate work on the use of PHER-O2 in ophthalmic surgery. In discussing the matter with Dr. Kwun, we feel that there is a significant market for our product. We will look to Dr. Kwun to act as our company lead on working toward an FDA approved ophthalmic indication."
Dr. Kwun added, "I have been following the development of Sanguine's PHER-O2 for sometime. I feel there is significant potential in using PHER-O2 for use in retinal surgery. Although the use of this product in retinal work is unknown at this point, I am proud to join the Medical Advisory Board to pursue an opportunity to evaluate PHER-O2 further."
Sanguine Corporation is a development-stage company focused on the research and development of PHER-O2, a synthetic red blood cell product with potential applications in a variety of specialties, including: transfusions, CAT scans, cardioplegia and the treatment of heart attacks, strokes, head and neck tumors and hemorrhagic shock. The Company is also developing non-medical applications for its perfluorocarbon (PFC) product.
For information related to the Sanguine Corporation, contact: Investor Relations: Michael Dancy, 801-746-3570, email: medancy@allwest.net, or visit: www.sanguine-corp.com.
Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the Company's products, increased levels of competition for the Company, new products and technological changes, the Company's dependence on third-party suppliers, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. These risks should be read in conjunction with this press release.
SOURCE: Sanguine Corporation
CONTACT: Sanguine Corporation
Michael Dancy, 801-746-3570
medancy@allwest.net |
